Group Lung Bacteria – Key Publications (1996-current)
Crough T, Fazou C, Weiss J, Campbell S, Davenport M, Bell SC, Galbraith A, McNeil K, Khanna R.
Symptomatic and Asymptomatic Viral Recrudescence in Solid Organ Transplant Recipients and its
Relationship with Antigen-Specific CD8+ T-cell Response. J. Virol. 2007; 81: 11538-11542.
McCormack J, Bell SC, Sennini S, Walmsley K, Patel K, Wainwright C, Serisier D, Harris M, Bowler S.
Daily versus weekly azithromycin in cystic fibrosis patients. ERJ 2007; 30: 487-495.
Hennig S, Waterhouse TH, Bell SC, France M, Wainwright CE, Miller H, Charles B, Duffull SB. A Doptimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis
patients. Brit J Clin Pharm 2007; 63: 438-450.
Hennig S, Wainwright C, Bell SC, Miller H, Friberg L, Charles B. Population pharmacokinetics of
itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone
marrow transplant patients. Clinical Pharmacokinetics 2006; 45: 1099-1114.
Block JK, Vandemheen KL, Tullis E, Fergusson D, Dousette S, Hasse D, Berthiaume Y, Brown N, Wilcox
P, Bye P, Bell SC, Noseworthy M, Pedder L, Freitag A, Paterson N, Aaron SD. Predictors of serious
pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant organisms.
Thorax 2006; 61: 969-74.
Buntain HM, Schulter PJ, Bell SC, Greer RM, Wong JCH, Batch J, Lewindon P, Wainwright CE. A
longitudinal study of bone mass accrual in Australian children and adolescents with cystic fibrosis.
Thorax 2006; 61: 146-154.
Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell SC, Elkins M, Thompson B, MacLeod C, Aaron S,
Harbour C. Antibiotic susceptibilities of Pseudomonas aeruginosa derived from patients with cystic
fibrosis under aerobic, anaerobic and biofilm conditions. J Clin Micro 2005; 43: 5085-5090.
Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, Berthiaume Y, Brown N, Wilcox
P, Bye P, Yozghatlian V, Bell SC, Chan F, Rose B, Jenaeret A, Stevenson A, Noseworthy M, Freitag A,
Paterson N, Doucette S, Harbour C, Ruel M, MacDonald N. Multiple combination antibiotic
susceptibility testing to treat exacerbations of cystic fibrosis associated with multi-resistant bacteria.
Lancet 2005; 366: 463-471.
O’Carroll MR, Syrmis MW, Wainwright CE, Greer RM, Mitchell P, Nissen MD, Coulter C, Sloots TP,
Bell SC. Clonal strains of Pseudomonas aeruginosa shared between paediatric and adult cystic
fibrosis centres. Eur Resp J 2004; 24: 101-106.
Buntain HM, Greer RM, Wong JCH, Schulter PJ, Powell E, Potter JM, Batch JA, Lewindon P,
Wainwright C, Bell SC. Low bone mineral density in Australian children and adults with cystic fibrosis
despite normal vitamin D status. Thorax 2004; 59: 149-155.
O’Carroll MR, Kidd TJ, Smith H, Rose B, Harbour C, Coulter C, Bell SC. Burkholderia pseudomallei:
another emerging pathogen in cystic fibrosis? Thorax 2003; 58: 1087-1091.
Skerritt MA, Bharadwaj M, Burrows JM, Morrison L, Davies J, Kear LM, Slaughter R, Bell SC, Galbraith
AJ, Khanna R, Moss DJ. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is
coincident with long-term recovery from post-transplant lymphoma after adoptive immunotherapy.
Transplantation 2003; 75: 1556-60.
Wolter J, Seeney S, Bell SC, Bowler SD, Masel PJ, McCormack J. Long-term azithromycin therapy
improves disease parameters in cystic fibrosis – a randomised control trial. Thorax 2002; 57: 212216.
Khanna R, Bell SC, Sherritt M, Galbraith AJ, Burrows SR, Rafter L, Clarke B, Slaughter R, Falk MC,
Douglass J, Williams T, Elliott SL, Moss DJ. Activation and Adoptive transfer of Epstein-Barr VirusSpecific Cytotoxic T cells in Solid Organ Transplant Patients with Post Transplant Lymphoproliferative
Disease. Proc Natl Acad Sci 1999; 96: 10391-10396. (RK and SCB contributed equally to this work).
Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ. Circulating immunoreactive interleukin-6 in cystic
fibrosis. Am J Respir Crit Care Med 1998; 157: 1764-1769.
Field PI, Simmel R, Bell SC, Allen DH, Berend N. Evidence for opioid modulation and generation of
prostaglandins in SO2-induced bronchoconstruction. Thorax 1996;51: 159-163.
Bell SC, Saunders MJ, Elborn JS, Shale DJ. Resting energy expenditure and oxygen cost of respiration
in patients with cystic fibrosis. Thorax 1996;51: 126-131.
Bell SC, Robinson PJ. Prevention of acute exacerbations in cystic fibrosis (review). Thorax 2007; 62:
723-732.
Elborn JS, Bell SC. Editorial. Exacerbations in patients with cystic fibrosis and bronchiectasis. Thorax
2007; 63: 288-290.
Yang IA, Kim ST, Bell SC. Antibiotic therapy for chronic obstructive lung disease, bronchiectasis and
cystic fibrosis. In: Evidence-based Respiratory Medicine. Editor: P. Gibson. Blackwell Publishing.
2005.